United Therapeutics Corporation (UTHR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Silver Spring, MD, United States. The current CEO is Martine A. Rothblatt.
UTHR has IPO date of 1999-06-17, 1,305 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $25.36B.
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with chronic and life-threatening diseases, particularly pulmonary hypertension and related conditions. The company's commercial portfolio includes Remodulin, Tyvaso, Orenitram, and Adcirca for treating pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. United Therapeutics maintains an active pipeline of innovative treatments including gene therapies, advanced drug delivery systems, and next-generation formulations, supported by strategic partnerships with leading medical device and pharmaceutical companies. Headquartered in Silver Spring, Maryland, the company operates globally to address significant unmet medical needs in pulmonary hypertension and oncology.
